Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

Comparative effectiveness of malaria prevention measures: a systematic review and network meta-analysis.

Wangdi K, Furuya-Kanamori L, Clark J, Barendregt JJ, Gatton ML, Banwell C, Kelly GC, Doi SAR, Clements ACA.

Parasit Vectors. 2018 Mar 27;11(1):210. doi: 10.1186/s13071-018-2783-y.

2.

Antimalarial drugs and the prevalence of mental and neurological manifestations: A systematic review and meta-analysis.

Bitta MA, Kariuki SM, Mwita C, Gwer S, Mwai L, Newton CRJC.

Wellcome Open Res. 2017 Jun 2;2:13. doi: 10.12688/wellcomeopenres.10658.2. eCollection 2017.

4.

Primaquine in Plasma and Methemoglobinemia in Patients with Malaria Due to Plasmodium vivax in the Brazilian Amazon Basin.

Vieira JL, Ferreira MES, Ferreira MVD, Gomes MM.

Am J Trop Med Hyg. 2017 May;96(5):1171-1175. doi: 10.4269/ajtmh.15-0368. Epub 2017 Apr 5.

PMID:
28440745
5.

Two Novel Calcium-Dependent Protein Kinase 1 Inhibitors Interfere with Vertical Transmission in Mice Infected with Neospora caninum Tachyzoites.

Müller J, Aguado-Martínez A, Balmer V, Maly DJ, Fan E, Ortega-Mora LM, Ojo KK, Van Voorhis WC, Hemphill A.

Antimicrob Agents Chemother. 2017 Mar 24;61(4). pii: e02324-16. doi: 10.1128/AAC.02324-16. Print 2017 Apr.

6.

Concurrent Inflammation Augments Antimalarial Drugs-Induced Liver Injury in Rats.

Niknahad H, Heidari R, Firuzi R, Abazari F, Ramezani M, Azarpira N, Hosseinzadeh M, Najibi A, Saeedi A.

Adv Pharm Bull. 2016 Dec;6(4):617-625. doi: 10.15171/apb.2016.076. Epub 2016 Dec 22.

7.

Management of relapsing Plasmodium vivax malaria.

Chu CS, White NJ.

Expert Rev Anti Infect Ther. 2016 Oct;14(10):885-900. doi: 10.1080/14787210.2016.1220304. Epub 2016 Aug 31. Review.

8.

TSCQ study: a randomized, controlled, open-label trial of daily trimethoprim-sulfamethoxazole or weekly chloroquine among adults on antiretroviral therapy in Malawi: study protocol for a randomized controlled trial.

Laurens MB, Mungwira RG, Nyirenda OM, Divala TH, Kanjala M, Muwalo F, Mkandawire FA, Tsirizani L, Nyangulu W, Mwinjiwa E, Taylor TE, Mallewa J, Blackwelder WC, Plowe CV, Laufer MK, van Oosterhout JJ.

Trials. 2016 Jul 18;17(1):322. doi: 10.1186/s13063-016-1392-3.

9.

Psychiatric effects of malaria and anti-malarial drugs: historical and modern perspectives.

Nevin RL, Croft AM.

Malar J. 2016 Jun 22;15:332. doi: 10.1186/s12936-016-1391-6. Review.

10.

The Interactions of P-Glycoprotein with Antimalarial Drugs, Including Substrate Affinity, Inhibition and Regulation.

Senarathna SM, Page-Sharp M, Crowe A.

PLoS One. 2016 Apr 5;11(4):e0152677. doi: 10.1371/journal.pone.0152677. eCollection 2016.

11.

Feasibility and acceptability of injectable artesunate for the treatment of severe malaria in the Democratic Republic of Congo.

Ntuku HM, Ferrari G, Burri C, Tshefu AK, Kalemwa DM, Lengeler C.

Malar J. 2016 Jan 8;15:18. doi: 10.1186/s12936-015-1072-x.

12.

Mefloquine inhibits chondrocytic proliferation by arresting cell cycle in G2/M phase.

Li Q, Chen ZG, Xia Q, Lin JP, Yan ZQ, Yao ZJ, Dong J.

Int J Clin Exp Pathol. 2015 Oct 1;8(10):12583-8. eCollection 2015.

13.

Confirmed Plasmodium vivax Resistance to Chloroquine in Central Vietnam.

Thanh PV, Hong NV, Van NV, Louisa M, Baird K, Xa NX, Peeters Grietens K, Hung le X, Duong TT, Rosanas-Urgell A, Speybroeck N, D'Alessandro U, Erhart A.

Antimicrob Agents Chemother. 2015 Dec;59(12):7411-9. doi: 10.1128/AAC.00791-15. Epub 2015 Sep 21.

14.

Quinine as a potential tracer for medication adherence: A pharmacokinetic and pharmacodynamic assessment of quinine alone and in combination with oxycodone in humans.

Babalonis S, Hampson AJ, Lofwall MR, Nuzzo PA, Walsh SL.

J Clin Pharmacol. 2015 Dec;55(12):1332-43. doi: 10.1002/jcph.557. Epub 2015 Jul 29.

15.
16.

Mefloquine and Its Enantiomers Are Active against Mycobacterium tuberculosis In Vitro and in Macrophages.

Bermudez LE, Meek L.

Tuberc Res Treat. 2014;2014:530815. doi: 10.1155/2014/530815. Epub 2014 Dec 11.

17.

Efficacy and safety of artemisinin combination therapy (ACT) for non-falciparum malaria: a systematic review.

Visser BJ, Wieten RW, Kroon D, Nagel IM, Bélard S, van Vugt M, Grobusch MP.

Malar J. 2014 Nov 26;13:463. doi: 10.1186/1475-2875-13-463. Review.

18.

Enantiomerically pure amino-alcohol quinolines: in vitro anti-malarial activity in combination with dihydroartemisinin, cytotoxicity and in vivo efficacy in a Plasmodium berghei mouse model.

Mullié C, Taudon N, Degrouas C, Jonet A, Pascual A, Agnamey P, Sonnet P.

Malar J. 2014 Oct 16;13:407. doi: 10.1186/1475-2875-13-407.

19.

Effects of nanoliposomal and pegylated nanoliposomal artemisinin in treatment of breast cancer.

Dadgar N, Koohi Moftakhari Esfahani M, Torabi S, Alavi SE, Akbarzadeh A.

Indian J Clin Biochem. 2014 Oct;29(4):501-4. doi: 10.1007/s12291-013-0389-x. Epub 2013 Oct 1.

20.

Atovaquone and quinine anti-malarials inhibit ATP binding cassette transporter activity.

Rijpma SR, van den Heuvel JJ, van der Velden M, Sauerwein RW, Russel FG, Koenderink JB.

Malar J. 2014 Sep 13;13:359. doi: 10.1186/1475-2875-13-359.

Supplemental Content

Support Center